Floatz logo

Benmelstobart

Advanced Acral Malignant Melanoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.monoclonal_antibodyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Advanced Acral Malignant Melanoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Yonsei University
Phase 2BB
Rivoceranib
Peking University Cancer Hospital & Institute
Phase 3B
Nilotinib
Institute of Cancer Research, United Kingdom
Phase 2B
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B
Imatinib
National Cancer Institute (NCI)
Phase 2B

View all 29 →

Same molecule, other indications

Benmelstobart is also rated in:

small cell lung carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
AnlotinibDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →